A phase I, double-blind, randomised, placebo-controlled, dose escalating study to assess the safety, tolerability, and pharmacokinetics of single and multiple doses of NVB302 administered orally to healthy volunteers.

Trial Profile

A phase I, double-blind, randomised, placebo-controlled, dose escalating study to assess the safety, tolerability, and pharmacokinetics of single and multiple doses of NVB302 administered orally to healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Apr 2016

At a glance

  • Drugs NVB 302 (Primary)
  • Indications Bacterial infections; Clostridium infections
  • Focus Adverse reactions
  • Most Recent Events

    • 23 Oct 2012 Actual end date changed from 21 Dec 2011 to 16 Mar 2012 as reported by ISRCTN.
    • 23 Oct 2012 Actual initiation date changed from 24 Aug 2011 to 26 Oct 2011 as reported by ISRCTN.
    • 22 Dec 2011 Actual end date (Dec 2011) added as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top